Eli Lilly Net Profit Margin 2010-2024 | LLY

Current and historical net profit margin for Eli Lilly (LLY) from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue. Eli Lilly net profit margin for the three months ending March 31, 2024 was .
Eli Lilly Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-03-31 $35.93B $6.14B 17.09%
2023-12-31 $34.12B $5.24B 15.36%
2023-09-30 $32.07B $4.99B 15.56%
2023-06-30 $29.52B $6.50B 22.02%
2023-03-31 $27.69B $5.69B 20.54%
2022-12-31 $28.54B $6.25B 21.88%
2022-09-30 $29.24B $6.03B 20.64%
2022-06-30 $29.07B $5.69B 19.58%
2022-03-31 $29.32B $6.13B 20.90%
2021-12-31 $28.32B $5.58B 19.71%
2021-09-30 $27.76B $5.97B 21.51%
2021-06-30 $26.73B $6.07B 22.71%
2021-03-31 $25.49B $6.09B 23.90%
2020-12-31 $24.54B $6.19B 25.24%
2020-09-30 $23.21B $5.57B 24.01%
2020-06-30 $22.95B $5.62B 24.48%
2020-03-31 $23.09B $5.53B 23.97%
2019-12-31 $22.32B $8.32B 37.27%
2019-09-30 $21.84B $7.95B 36.39%
2019-06-30 $21.67B $7.84B 36.19%
2019-03-31 $21.62B $6.26B 28.94%
2018-12-31 $21.49B $3.23B 15.04%
2018-09-30 $19.12B $0.45B 2.35%
2018-06-30 $19.47B $-0.14B -0.74%
2018-03-31 $19.71B $1.12B 5.70%
2017-12-31 $19.97B $-0.20B -1.02%
2017-09-30 $22.47B $2.23B 9.90%
2017-06-30 $22.01B $2.45B 11.12%
2017-03-31 $21.59B $2.19B 10.13%
2016-12-31 $21.22B $2.74B 12.90%
2016-09-30 $20.84B $2.44B 11.73%
2016-06-30 $20.61B $2.47B 11.97%
2016-03-31 $20.18B $2.32B 11.49%
2015-12-31 $19.96B $2.41B 12.07%
2015-09-30 $19.71B $2.36B 11.98%
2015-06-30 $19.62B $2.06B 10.50%
2015-03-31 $19.58B $2.19B 11.21%
2014-12-31 $19.62B $2.39B 12.19%
2014-09-30 $20.30B $2.69B 13.25%
2014-06-30 $21.20B $3.39B 16.00%
2014-03-31 $22.20B $3.86B 17.41%
2013-12-31 $23.11B $4.68B 20.26%
2013-09-30 $23.26B $4.78B 20.57%
2013-06-30 $22.93B $4.91B 21.40%
2013-03-31 $22.60B $4.63B 20.47%
2012-12-31 $22.60B $4.09B 18.09%
2012-09-30 $22.69B $4.12B 18.16%
2012-06-30 $23.40B $4.03B 17.22%
2012-03-31 $24.05B $4.30B 17.89%
2011-12-31 $24.29B $4.35B 17.90%
2011-09-30 $24.43B $4.66B 19.07%
2011-06-30 $23.93B $4.73B 19.75%
2011-03-31 $23.43B $4.88B 20.82%
2010-12-31 $23.08B $5.07B 21.97%
2010-09-30 $22.82B $4.82B 21.10%
2010-06-30 $22.73B $4.45B 19.59%
2010-03-31 $22.28B $4.26B 19.14%
2009-12-31 $21.84B $4.33B 19.83%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $840.044B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $637.050B 48.95
Johnson & Johnson (JNJ) United States $357.994B 14.22
Merck (MRK) United States $331.088B 60.24
AbbVie (ABBV) United States $300.886B 15.55
AstraZeneca (AZN) United Kingdom $244.568B 21.26
Novartis AG (NVS) Switzerland $215.070B 15.25
Pfizer (PFE) United States $157.191B 19.53
Sanofi (SNY) $119.570B 11.27
Innoviva (INVA) United States $0.993B 6.97